ArticleLupus science & medicine2026
Twelve-month follow-up after telitacicept withdrawal in patients with SLE: a single-centre study.
Article in Lupus science & medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the safety and durability of telitacicept treatment in patients with SLE by identifying the reasons for treatment discontinuation and potential risk factors for subsequent disease recurrence.
methodsThis retrospective study included 48 lupus patients who discontinued telitacicept and were under long-term follow-up at Peking Union Medical College Hospital. The underlying causes for treatment discontinuation and the subsequent disease outcomes were analysed.
resultsThis study found that, among 48 patients who discontinued telitacicept, 18 (37.5%, 18/48) did so due to achieving a lupus low disease activity state (LLDAS), based on physician recommendations. Primary adverse discontinuation reasons included disease status changes necessitating treatment adjustment (16.7%, 8/48), decreased immunoglobulin G levels (6.2%, 3/48) and infection/fever (6.2%, 3/48). Among the 40 patients without changes to concomitant therapies post discontinuation, 30 (75%) maintained relatively stable Systemic Lupus Erythematosus Disease Activity Index scores, while 10 (25%) showed increased scores during the 12-month follow-up. Based on the characteristics at the time of telitacicept withdrawal, a high rate of central nervous system involvement was observed among patients who exhibited active disease after discontinuation. No significant fluctuations in serological markers were observed during the 12-month postdiscontinuation period (p>0.05 for all comparisons).
conclusionsThe majority of patients (37.5%) discontinued telitacicept due to achieving LLDAS. During the 12-month follow-up after drug withdrawal, 75% (30/40) of patients remained stable, whereas 25% had disease progression. A higher proportion of neurological involvement was observed in patients with disease changes after drug withdrawal, suggesting that patients with major organ involvement should be carefully evaluated following treatment cessation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.